Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026
Gene Solutions presented new research at the ISPD 2026 conference regarding advancements in prenatal genomic screening and AI-enabled pregnancy risk assessment. The company emphasized the role of responsible innovation in expanding access to genomic medicine.
Why it matters
These advancements represent a shift toward more personalized and minimally invasive prenatal care, potentially improving health outcomes for mothers and infants globally.
As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health.
SINGAPORE , July 22, 2026 /PRNewswire/ -- Gene Solutions , a global biotechnology company focused on accessible and responsible genomics, participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), held virtually from July 7–9. Across an industry symposium, a scientific session, two oral presentations and three scientific posters, the company presented data and expert perspectives on how genomics, epigenomics and artificial intelligence may support more comprehensive, personalized and minimally invasive care throughout pregnancy and across women's health.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in